196 related articles for article (PubMed ID: 22280402)
1. "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
Caboni L; Kinsella GK; Blanco F; Fayne D; Jagoe WN; Carr M; Williams DC; Meegan MJ; Lloyd DG
J Med Chem; 2012 Feb; 55(4):1635-44. PubMed ID: 22280402
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships in non-ligand binding pocket (non-LBP) diarylhydrazide antiandrogens.
Caboni L; Egan B; Kelly B; Blanco F; Fayne D; Meegan MJ; Lloyd DG
J Chem Inf Model; 2013 Aug; 53(8):2116-30. PubMed ID: 23834240
[TBL] [Abstract][Full Text] [Related]
3. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
4. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
[TBL] [Abstract][Full Text] [Related]
5. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
6. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
7. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
9. Development of 2-(5,6,7-Trifluoro-1
Leblanc E; Ban F; Cavga AD; Lawn S; Huang CF; Mohan S; Chang MEK; Flory MR; Ghaidi F; Lingadahalli S; Chen G; Yu IPL; Morin H; Lallous N; Gleave ME; Mohammed H; Young RN; Rennie PS; Lack NA; Cherkasov A
J Med Chem; 2021 Oct; 64(20):14968-14982. PubMed ID: 34661404
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
11. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
12. NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.
Papaioannou M; Schleich S; Roell D; Schubert U; Tanner T; Claessens F; Matusch R; Baniahmad A
Invest New Drugs; 2010 Dec; 28(6):729-43. PubMed ID: 19771394
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
[TBL] [Abstract][Full Text] [Related]
15. Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors.
Helsen C; Nguyen TT; Lee XY; Eerlings R; Louros N; Schymkowitz J; Rousseau F; Claessens F; Voet A
Mol Cancer Ther; 2022 Dec; 21(12):1823-1834. PubMed ID: 36218067
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates.
George A; Raji I; Cinar B; Kucuk O; Oyelere AK
Bioorg Med Chem; 2018 May; 26(8):1481-1487. PubMed ID: 29456113
[TBL] [Abstract][Full Text] [Related]
17. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
Dehm SM; Tindall DJ
J Biol Chem; 2006 Sep; 281(38):27882-93. PubMed ID: 16870607
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
19. Improving Strategies in the Development of Protein-Downregulation-Based Antiandrogens.
Zhang R; Huang C; Xiao X; Zhou J
ChemMedChem; 2021 Jul; 16(13):2021-2033. PubMed ID: 33554455
[TBL] [Abstract][Full Text] [Related]
20. Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
Ryu BJ; Kim N; Kim JT; Koo TS; Yoo SE; Jeong SH; Kim SH; Kang NS
Bioorg Med Chem Lett; 2013 Jul; 23(13):3887-90. PubMed ID: 23727044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]